# US 8,278,325 B2 · Nitrogen-containing heteroaryl compounds and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,325 B2
- Document ID: US8278325B2
- Status: Granted
- Kind: B2
- Application number: 13/186,351
- Filed: 2011-07-19
- Published: 2012-02-02
- Granted: 2012-10-02
- Earliest claimed: 2003-06-06
- Assignees: FibroGen, Inc.
- Inventors: Michael P. Arend; Lee A. Flippin; Volkmar Guenzler-Pukall; Wen-Bin Ho; Eric Turtle; Xiaohui Du
- Web page: https://patentgrep.com/patent/US8278325B2

## CPC

- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 38/1816: {Erythropoietin [EPO]}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 221/08: Aza-anthracenes
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 217/24: Oxygen atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

## Claims

### Claim 1

A compound represented by formula:
wherein:
R1 is selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, and —XR6 where X is oxygen, —S(O)n— or —NR7— where n is zero, one or two, R6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R7 is hydrogen, alkyl or aryl or, when X is —NR7—, then R7 and R6, together with the nitrogen atom to which they are bound, can be joined to form a heterocyclic or substituted heterocyclic group; and
R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxy, cyano, —S(O)n—N(R6)—R6 where n is 0, 1, or 2, —NR6C(O)NR6R6, and —XR6 where X is oxygen, —S(O)n— or —NR7— where n is zero, one or two, each R6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic provided that when X is —SO— or —SO2—, then R6 is not hydrogen, and R7 is selected from the group consisting of hydrogen, alkyl, and aryl, or R2, R3 together with the carbon atom pendent thereto, form an aryl substituted aryl, heteroaryl, or substituted heteroaryl;
or a pharmaceutically acceptable salt, ester, or amide thereof;
with the proviso that at least one of the following occurs:
1) R1 is fluoro, bromo, iodo, alkyl, substituted alkyl, alkoxy, aminoacyl, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, or —XR6 where X is oxygen, —S(O)n— or —NR7— where n is zero, one or two, R6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R7 is hydrogen, alkyl or aryl; or
2) R2 is substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, fluoro, iodo, cyano, or —XR6 where X is oxygen, —S(O)n— or —NR7— where n is zero, one or two, R6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R7 is hydrogen, alkyl or aryl provided that:
a) when R2 is substituted alkyl such a substituent does not include trifluoromethyl;
b) —XR6 is not alkoxy; and
c) when —XR6 is substituted alkoxy such a substituent does not include benzyl or benzyl substituted by a substituent selected from the group consisting of (C1-C5) alkyl and (C1-C5) alkoxy or does not include a fluoroalkoxy substituent of the formula:
—O—[CH2]x—CfH(2f+1−g)Fg
where x is zero or one; f is an integer of from 1 to 5; and g is an integer of from 1 to (2f+1); or
3) R3 is substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, bromo, iodo, or —XR6 where X is oxygen, —S(O)n— or —NR7— where n is zero, one or two, R6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R7 is hydrogen, alkyl or aryl provided that:
a) when R3 is substituted alkyl such a substituent does not include trifluoromethyl;
b) —XR6 is not alkoxy; and
c) when —XR6 is substituted alkoxy such a substituent does not include benzyl or benzyl substituted by a substituent selected from the group consisting of (C1-C5) alkyl and (C1-C5) alkoxy or does not include a fluoroalkoxy substituent of the formula:
—O—[CH2]x—CfH(2f+1−g)Fg
where x is zero or one; f is an integer of from 1 to 5; and g is an integer of from 1 to (2f+1).

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
R2 and R3 are independently selected from the group consisting of hydrogen and —XR6 where X is oxygen or sulfur, and each R6 is independently selected from the group consisting of aryl and substituted aryl;
with the proviso that at least one of the following occurs:
1) R1 is fluoro, bromo, iodo, alkyl, substituted alkyl, alkoxy, aminoacyl, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, or —XR6 where X is oxygen, —S(O)n— or —NR7— where n is zero, one or two, R6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R7 is hydrogen, alkyl or aryl;
2) R2 is —XR6 where X is oxygen or sulfur, and R6 is selected from the group consisting of aryl and substituted aryl; or
3) R3 is —XR6 where X is oxygen or sulfur, and R6 is selected from the group consisting of aryl and substituted aryl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
R2 and R3 are independently selected from the group consisting of hydrogen and —XR6 where X is oxygen or sulfur, each R6 is independently selected from the group consisting of aryl, and substituted aryl;
with the proviso that at least one of the following occurs:
1) R2 is —XR6 where X is oxygen or sulfur and R6 is selected from the group consisting of aryl and substituted aryl; or
2) R3 is —XR6 where X is oxygen or sulfur and R6 is selected from the group consisting of aryl and substituted aryl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein:
R2 is —XR6 where X is oxygen or sulfur, and R6 is aryl or aryl substituted with one or two substituents independently selected from the group consisting of halo, alkyl, alkyl substituted with up to three halo substituents, alkoxy, alkoxy substituted with up to three halo substituents, nitro, alkylsulfonamido, and arylsulfonamido; and
R3 is hydrogen.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R1 is selected from the group consisting of hydrogen, halo and alkyl.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising
one or more compounds of claim 1 or a pharmaceutically acceptable salt, ester, or amide thereof and
a pharmaceutically acceptable carrier or excipient.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 10 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 11 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 12 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 13 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 14 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 15 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 16 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 17 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 18 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 19 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 20 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 21 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 22 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 23 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.

### Claim 24 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is of the formula:
or a pharmaceutically acceptable salt, ester, or amide thereof.
